CAP-232

Across CCLE and GDSC cell-line panels, response to CAP-232 is significantly associated with the pathway activity of multiple pathways, with LUNG_NSCLC_LUSC cell lines showing a particularly strong set of associations.

The most reproducible CAP-232 response-associated pathways across cancer lineages are Peptidyl-methionine modification, Erythrocyte differentiation, and Positive regulation of nuclear division, each associated with drug response in up to 9 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The scatter plot shows the strongest observed association, CAP-232 response versus Peptidyl-methionine modification pathway activity in LUNG_NSCLC_LUSC (Pearson r = -0.70).

Pathway activity biomarkers of CAP-232 response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner pathway	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LUNG_NSCLC_LUSC	Peptidyl-methionine modification →	-0.302	-0.761	<.001	<.001	3	9
KIDNEY	Erythrocyte differentiation →	+0.045	+0.345	.009	.019	3	7
BLOOD_Myeloma	Positive regulation of nuclear division →	+0.101	+0.481	.023	.002	3	7
BONE	Erythrocyte homeostasis →	+0.066	+0.878	.002	<.001	3	7
PANCREAS	Regulation of G2/M transition of mitotic cell cycle →	+0.051	+0.394	.011	.020	3	6
BLOOD_Leukemia	Negative regulation of cell cycle process →	+0.044	+0.440	.003	.009	3	6

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

CAP-232 response vs Peptidyl-methionine modification — LUNG_NSCLC_LUSC

Explore this scatter interactively →